Literature DB >> 22289971

Value of MRI as a surrogate marker for PML in natalizumab long-term therapy.

I Ayzenberg, C Lukas, N Trampe, R Gold, K Hellwig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22289971     DOI： 10.1007/s00415-012-6426-5

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  5 in total

1.  Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy.

Authors:  Ingo Kleiter; Michael Schröder; Ralf Lürding; Gerhard Schuierer; David B Clifford; Ulrich Bogdahn; Andreas Steinbrecher; Peter Pöschl
Journal:  Mult Scler       Date:  2010-05-07       Impact factor: 6.312

Review 2.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

3.  Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  P Vermersch; L Kappos; R Gold; J F Foley; T Olsson; D Cadavid; C Bozic; S Richman
Journal:  Neurology       Date:  2011-05-17       Impact factor: 9.910

4.  Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.

Authors:  Christos Vaklavas; Elsa P Sotelo-Rafiq; Jordan Lovy; Miguel A Escobar; Apostolia M Tsimberidou
Journal:  Virol J       Date:  2010-09-28       Impact factor: 4.099

5.  Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

Authors:  Hans Lindå; Anders von Heijne; Eugene O Major; Caroline Ryschkewitsch; Johan Berg; Tomas Olsson; Claes Martin
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245
  5 in total
  10 in total

Review 1.  Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy.

Authors:  Martyn K White; Ilker K Sariyer; Jennifer Gordon; Serena Delbue; Valeria Pietropaolo; Joseph R Berger; Kamel Khalili
Journal:  Rev Med Virol       Date:  2015-12-14       Impact factor: 6.989

Review 2.  Monoclonal antibodies as disease modifying therapy in multiple sclerosis.

Authors:  Erin E Longbrake; Becky J Parks; Anne H Cross
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

3.  Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Clemens Warnke; Gloria von Geldern; Philipp Markwerth; Thomas Dehmel; Robert Hoepner; Ralf Gold; Michael Pawlita; Tania Kümpfel; Mathias Mäurer; Martin Stangel; Florian Wegner; Reinhard Hohlfeld; Vera Straeten; Volker Limmroth; Thomas Weber; Derik Hermsen; Christoph Kleinschnitz; Hans-Peter Hartung; Mike P Wattjes; Anders Svenningson; Eugene Major; Tomas Olsson; Bernd C Kieseier; Ortwin Adams
Journal:  Ann Neurol       Date:  2014-05-08       Impact factor: 10.422

Review 4.  Natalizumab therapy for multiple sclerosis.

Authors:  Jeremy Chataway; David H Miller
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 5.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

Review 6.  Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.

Authors:  Ilya Ayzenberg; Robert Hoepner; Ingo Kleiter
Journal:  Ther Clin Risk Manag       Date:  2016-02-19       Impact factor: 2.423

7.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

Review 8.  Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.

Authors:  Raed A Alroughani; Hany M Aref; Saeed A Bohlega; Maurice P Dahdaleh; Imed Feki; Mohammed A Al Jumah; Muhammad Z Al-Kawi; Salam F Koussa; Mohamad A Sahraian; Isa A Alsharoqi; Bassem I Yamout
Journal:  BMC Neurol       Date:  2014-02-12       Impact factor: 2.474

9.  Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

Authors:  Tuan Dong-Si; Sandra Richman; Mike P Wattjes; Made Wenten; Sarah Gheuens; Jeffrey Philip; Shoibal Datta; James McIninch; Carmen Bozic; Gary Bloomgren; Nancy Richert
Journal:  Ann Clin Transl Neurol       Date:  2014-10-09       Impact factor: 4.511

Review 10.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.